– LentiGlobin in transfusion-dependent β-thalassemia (TDT) planned to be filed for marketing authorization in 2018 – – bb2121 in relapsed/refractory multiple myeloma planned to be filed for marketing ...
As the chart shows, the stock price benefited from three large jumps in June, August, and December. Here's how it went down. In June, at the annual American Society of Clinical Oncology (ASCO) meeting ...
bluebird bio (NASDAQ: BLUE) reported fourth-quarter earnings after the closing bell on Wednesday. Without any products on the market, the quarterly pipeline update is more important than the revenue ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T ...
It was a heck of a year for bluebird bio (NASDAQ: BLUE), with shares more than tripling in 2017, although they pulled back a little in December; the biotech ended the year up only 188.7%. As the chart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback